top of page
  • Writer's pictureJose Garcia

Bioinformatics Second Act

Updated: Dec 21, 2023

Bioinformatics has a rich history spanning over two decades, becoming a well-established technology. Thanks to high-performance computing and advanced hardware, it has paved the way for groundbreaking drug discovery, nutrition analysis, and cancer treatment developments. The extensive processing of data from various sources opens up exciting testing and modeling opportunities.


In this era of bioinformatics, we witness the emergence of new research areas and innovative treatment modalities, such as personalized immunotherapy and proteinomics, ushering in a revolution in cancer care and beyond. As this technology continues to mature, what lies ahead for bioinformatics? Let's take a sneak peek through the eyes of a bioinformatics expert.

Carl-Johan Ivarsson is the CEO of Qlucore which produces visualization-based bioinformatics data analysis tools for research and precision diagnostics.

Q:What advice would you give to someone who is interested in pursuing a career in bioinformatics, and how can they prepare themselves for the field?

A: At Qlucore we combine expertise from many fields such as mathematics, bioinformatics and software engineering. My advice, for what it is worth, would be to learn the basic principles of mathematics and statistics well. That will enable you to understand many methods and evolve with the field.

Q:Can you highlight some of the projects Qlucore has been involved in. What kinds of research is it making possible?

A: At Qlucore we are working within two segments. Software for data analysis (Qlucore Omics Explorer) and software for precision diagnostics (Qlucore Insights). For the first segment we deliver software solutions to customers in 25 countries who have written more than 1000 articles in peer-review journals using our solutions. In short it spans all type of omics data.
For the second segment we develop AI- based machine learning classifiers for subtyping of cancer based on gene expression signatures. We currently work with Leukemia, Non small cell lung cancer, breast cancer and bladder cancer.

Q: What exciting developments do you see over the next five years in bioinformatics?

A: I think we will see a lot of multi-omics analysis and of course AI.


About Radency

Radency is a software development company dedicated to streamlining operations for healthcare companies and improving patient care through innovative solutions. Our team of experienced software engineers, well-versed in the challenges faced by healthcare organizations, crafts custom software like EMR systems, mobile apps for remote monitoring, and secure tele-health platforms. 

By forging long-term partnerships with our clients, Radency ensures our software continuously evolves to meet the ever-changing needs of the healthcare landscape.

Read more about our healthcare projects by the link.


bottom of page